,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'bcsm']
summary slide highlights survival benefit of t-dxd therapy in mbc #asco22 #bcsm 
Regional Cancer Research Director @CleveClinicFl #Scientist #Immune #Oncology #Epigenetics #Cancer #Sensitisation #TIME #StayPositive. Tweets are mine.